]>A Current Review of Targeted Therapeutics for Ovarian Cancer : Table 4
Table 4: PARP inhibitors and ovarian cancer.
clinical trial.gov IDTherapeutic regimenStudy PI
NCT00753545AZD2281 in platinum sensitive EOCJ. Lederman
NCT00679783AZD2281 in known BRCA or recurrent EOCK. Gelman
NCT00749502MK4827 in BRCA mutant ovarian cancer
NCT00664781AG014699 in BRCA mutant ovarian cancerR. Plummer
NCT00647062AZD2281 and carboplatin in BRCA mutant EOCE. Kohn